Late anthracycline cardiotoxicity in patients treated for childhood acute lymphoblastic leukemia

Authors

  • Tamara Cedré Hernández Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara
  • Liliana Martínez Cárdenas Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara
  • Marta Beatriz García Caraballoso Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara
  • Alejandro González Díaz Cardiocentro “Ernesto Che Guevara”, Santa Clara
  • Guillermo González Ojeda Hospital Pediátrico “José Luis Miranda”, Santa Clara, Villa Clara
  • Alina Castillo Villocht Cardiocentro “Ernesto Che Guevara”, Santa Clara

Keywords:

cardiotoxins, anthracyclines, precursor cell lymphoblastic leukemia-lymphoma, child

Abstract

Introduction: advances in the treatment of childhood acute lymphoblastic leukemia give a greater life expectancy for these patients. As the number of survivors increase, more long-term adverse effects are detected. Among the most frequent adverse effects stands late anthracycline cardiotoxicity (doxorubicin and daunorubicin), drugs widely used in almost all chemotherapy regimens, but which are related to cardiovascular damage.
Objective: To describe the major late cardiovascular changes which are secondary to the use of chemotherapy for acute lymphoblastic leukemia diagnosed in childhood.
Material and methods: A descriptive, longitudinal and retrospective study was conducted with 82 patients diagnosed with acute lymphoblastic leukemia, aged between zero and 15 years of age in the Oncohematology Department of the José Luis Miranda Pediatric University Hospital of Villa Clara from 1969 and 2009, who completed the planned treatment and were followed up in consultation from the moment of stopping treatment until May 2012. The patients who died before the study, those who received no treatment with anthracyclines and those who did not cooperate with the investigation were excluded. The cumulative dose of anthracyclines received and the time elapsed between the administration of the last dose and the beginning of the study was estimated in all patients. All patients were assessed by physical examination, electrocardiogram and echocardiogram. To assess systolic function, the left ventricular ejection fraction and the shortening fraction were measured; and for diastolic function, the E and A waves and the E/A relationship were measured.
Results: Subclinical late cardiotoxicity predominated in patients treated with anthracyclines, which affected both sexes equally, with no significant differences concerning the age at diagnosis, or cumulative doses received. More cases affected appeared with increasing follow-up time.

 


Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Cedré Hernández T, Martínez Cárdenas L, García Caraballoso MB, González Díaz A, González Ojeda G, Castillo Villocht A. Late anthracycline cardiotoxicity in patients treated for childhood acute lymphoblastic leukemia. Acta Méd Centro [Internet]. 2013 Oct. 7 [cited 2025 Jun. 27];7(3):23-8. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/4

Issue

Vol. 7 No. 3 (2013): July-September

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).